AGIOS PHARMACEUTICALS INC(NASDAQ:AGIO) stock News

AGIO Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Chartmill - Mentions: AEO NCI CAL AIHS ...

Top movers in Thursday's pre-market session

13 hours ago - By: Benzinga - Mentions: PBM MTNB HSDT SSKN ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

8 days ago - By: Schall Law Firm

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

9 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

10 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

13 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

15 days ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

18 days ago - By: Zacks Investment Research - Mentions: ADPT ALLO AKRO

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

19 days ago - By: Stocktwits - Mentions: VFMO IWMW

Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More

20 days ago - By: Agios Pharmaceuticals, Inc.

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

20 days ago - By: Zacks Investment Research - Mentions: VRTX

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

26 days ago - By: Yahoo Finance - Mentions: BAC

Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders

2 months ago - By: Stocktwits

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns

2 months ago - By: Agios Pharmaceuticals, Inc.

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

2 months ago - By: The Motley Fool

Agios (AGIO) Q2 Revenue Jumps 45%

2 months ago - By: Agios Pharmaceuticals, Inc.

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

2 months ago - By: Benzinga - Mentions: BSAC BGC RMNI MTZ ...

Earnings Scheduled For July 31, 2025

2 months ago - By: Agios Pharmaceuticals, Inc.

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

3 months ago - By: Agios Pharmaceuticals, Inc.

Agios Appoints Dr. Jay Backstrom to Board of Directors

3 months ago - By: Yahoo Finance

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential

3 months ago - By: Yahoo Finance - Mentions: MS CNC RY RY.CA ...

Morgan Stanley Sees 8.8% EPS CAGR for Centene (NYSE:CNC), Initiates Coverage with $70 target.

3 months ago - By: Yahoo Finance - Mentions: BLND SNY NVDA TSM ...

Covius Services to Acquire Blend Labs’ (BLND) Title365 Holding Co

3 months ago - By: Yahoo Finance - Mentions: TTGT BAC QCOM PLD

Craig-Hallum Reiterates a Buy Rating on TechTarget (TTGT)

3 months ago - By: Yahoo Finance - Mentions: ELV ACGL ARQT AZN ...

Truist Lowers Elevance Health (ELV) to $500, Keeps Buy Rating

4 months ago - By: Yahoo Finance - Mentions: TSLA AMZN PINS AMAT ...

AGIOS PHARMACEUTICALS INC (AGIO) Stock News

AGIO Latest News, Press Relases and Analysis

Top movers in Thursday's pre-market session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. – AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia

Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

Agios Pharmaceuticals, Inc. (AGIO) Advances Pipeline With Tebapivat, AG-236 in Rare Blood Disorders

Agios Retail Buzz Surges On Saudi Thalassemia Nod As Retail Hails ‘Incredible Recovery’ Despite FDA Concerns

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios (AGIO) Q2 Revenue Jumps 45%

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Earnings Scheduled For July 31, 2025

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET

Agios Appoints Dr. Jay Backstrom to Board of Directors

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential

Morgan Stanley Sees 8.8% EPS CAGR for Centene (NYSE:CNC), Initiates Coverage with $70 target.

Covius Services to Acquire Blend Labs’ (BLND) Title365 Holding Co

Craig-Hallum Reiterates a Buy Rating on TechTarget (TTGT)

Truist Lowers Elevance Health (ELV) to $500, Keeps Buy Rating

Equity Markets Rise Intraday After Trump-Xi Call; Tesla Slides